Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mesoblast Limited ( (AU:MSB) ) has shared an update.
Mesoblast Limited announced the application for the quotation of 3,000,000 ordinary fully paid securities on the Australian Securities Exchange (ASX). These securities are issued under an employee incentive scheme and are not subject to transfer restrictions. This move is part of Mesoblast’s strategy to enhance its market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder engagement positively.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.11 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development and commercialization of innovative cellular medicines. The company primarily targets conditions related to inflammation and immune-mediated diseases, leveraging its proprietary mesenchymal lineage cell therapy technology.
Average Trading Volume: 5,377,053
Technical Sentiment Signal: Buy
Current Market Cap: A$3.7B
See more insights into MSB stock on TipRanks’ Stock Analysis page.